Format

Send to

Choose Destination
Oncotarget. 2016 Sep 13;7(37):60698-60711. doi: 10.18632/oncotarget.10849.

Microenvironment drug resistance in multiple myeloma: emerging new players.

Author information

1
Department of Biomedical Sciences and Human Oncology, Internal Medicine Section, University of Bari Medical School, Bari, Italy.
2
Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy.
3
Department of Biomedical Sciences and Human Oncology, General Pathology Section, Bari, Italy.

Abstract

Multiple myeloma (MM) drug resistance (DR) is a multistep transformation process based on a powerful interplay between bone marrow stromal cells and MM cells that allows the latter to escape anti-myeloma therapies. Here we present an overview of the role of the bone marrow microenvironment in both soluble factors-mediated drug resistance (SFM-DR) and cell adhesion-mediated drug resistance (CAM-DR), focusing on the role of new players, namely miRNAs, exosomes and cancer-associated fibroblasts.

KEYWORDS:

cancer-associated fibroblasts; drug resistance; exosomes; microRNAs; multiple myeloma

PMID:
27474171
PMCID:
PMC5312413
DOI:
10.18632/oncotarget.10849
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center